Who are HIP2101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low dose valproate, Vorinostat (VOR), SPARC0912, MC0518, AL8326 tablets, Belinostat Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hip2101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

HIP2101 — Competitive Intelligence Brief

HIP2101 (HIP2101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase (HDAC) inhibitor. Area: Oncology.

phase 3 Histone deacetylase (HDAC) inhibitor Histone deacetylase (HDAC) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HIP2101 (HIP2101) — Hanmi Pharmaceutical Company Limited. HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HIP2101 TARGET	HIP2101	Hanmi Pharmaceutical Company Limited	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)
Low dose valproate	Low dose valproate	Mario Negri Institute for Pharmacological Research	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDACs)
Vorinostat (VOR)	Vorinostat (VOR)	University of North Carolina, Chapel Hill	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)
SPARC0912	SPARC0912	Sun Pharma Advanced Research Company Limited	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)
MC0518	MC0518	medac GmbH	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)
AL8326 tablets	AL8326 tablets	Advenchen Laboratories Nanjing Ltd.	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)
Belinostat Injection	Belinostat Injection	Acrotech Biopharma Inc.	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase (HDAC) inhibitor class)

Acrotech Biopharma Inc. · 1 drug in this class
Advenchen Laboratories Nanjing Ltd. · 1 drug in this class
BeBetter Med Inc · 1 drug in this class
Hanmi Pharmaceutical Company Limited · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Sun Pharma Advanced Research Company Limited · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class
medac GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HIP2101 — Competitive Intelligence Brief. https://druglandscape.com/ci/hip2101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab